Coherus Oncology (CHRS) Net Cash Flow (2013 - 2026)
Coherus Oncology (CHRS) posted Net Cash Flow of $26.4 million for Q1 2026, up 282.13% sequentially from -$14.5 million in Q4 2025, and up 160.49% YoY from $10.1 million in Q1 2025.
Coherus Oncology (CHRS) Net Cash Flow (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Net Cash Flow for 14 years, with the latest figure at $26.4 million in Q1 2026.
- Quarterly Net Cash Flow rose 160.49% year-over-year to $26.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.8 million (up 118.48% YoY) and the FY2025 annual result came in at -$37.1 million, down 262.09% from the prior year.
- Net Cash Flow rose to $26.4 million in Q1 2026 per CHRS's latest filing, from -$14.5 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $156.9 million in Q1 2024 and troughed at -$223.3 million in Q4 2022.
- A 5-year average of -$17.8 million and a median of -$14.5 million in 2025 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 430.96% in 2024, down 939.87% in 2024.
- Over 5 years, Net Cash Flow stood at -$223.3 million in 2022, then soared by 110.14% to $22.6 million in 2023, then grew by 25.03% to $28.3 million in 2024, then slumped by 151.15% to -$14.5 million in 2025, then soared by 282.13% to $26.4 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $26.4 million, -$14.5 million, and -$113.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | -32.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.32 Mn |
| Jun 30, 2026 | -32.32 Mn |
| Mar 31, 2026 | 26.36 Mn |
| Mar 31, 2026 | 26.36 Mn |
| Dec 31, 2025 | -14.47 Mn |
| Dec 31, 2025 | -14.47 Mn |
| Sep 30, 2025 | -113.56 Mn |
| Sep 30, 2025 | -113.56 Mn |
| Jun 30, 2025 | 134.48 Mn |
| Jun 30, 2025 | 134.48 Mn |
| Mar 31, 2025 | -43.58 Mn |
| Mar 31, 2025 | -43.58 Mn |
| Dec 31, 2024 | 28.30 Mn |
| Dec 31, 2024 | 28.30 Mn |
| Sep 30, 2024 | -61.74 Mn |
| Sep 30, 2024 | -61.74 Mn |
| Jun 30, 2024 | -100.54 Mn |
| Jun 30, 2024 | -100.54 Mn |
| Mar 31, 2024 | 156.88 Mn |
| Mar 31, 2024 | 156.88 Mn |